Activating mutations and MET gene amplification have been found in lung cancer cell lines and primary tumours, resulting in the constitutive activation of the pathway and its cellular effects in cell line models (Bardelli et al, 1998; Peschard et al, 2001; Ma et al, 2003; Kong-Beltran et al, 2006; Engelman et al, 2007; Lutterbach et al, 2007). The gene discussed is MET; the disease is neoplasm.